Leiling Liu1, Hao Lei1, Jiahui Hu1, Ying Tang1, Danyan Xu2. 1. Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. 2. Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. xudanyan02@csu.edu.cn.
Abstract
BACKGROUND: Direct oral anticoagulants (DOACs) combined with antiplatelet therapy for acute coronary syndrome (ACS) may reduce ischemic events, but there is no consensus on bleeding risk. Moreover, the effect of DOACs on stable coronary artery disease (CAD) needs to be elucidated. We conducted a meta-analysis to summarize the efficacy and safety of DOACs combined with antiplatelet therapy in the treatment of stable CAD and ACS. METHODS: We searched PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials, then performed a systematic review of all 17 randomized controlled trials. RESULTS: For patients with stable CAD, DOACs combined with antiplatelet therapy significantly reduced the rate of major adverse cardiovascular events (MACE) (risk ratio; 95% confidence interval: 0.88; 0.81-0.95) and ischemic stroke (0.62; 0.50-0.77), with a relatively low risk of major bleeding (1.72; 1.42-2.07). For patients with ACS, the combination of DOACs reduced the risk of MACE (0.91; 0.85-0.97), myocardial infarction (MI) (0.90; 0.83-0.98), and ischemic stroke (0.75; 0.58-0.97), accompanied by increased non-fatal bleeding events and intracranial hemorrhage (3.42; 1.76-6.65). Results were similar when restricting the analysis to phase III studies except for the rate of stroke in patients with ACS. CONCLUSIONS: Combination therapy reduced the incidence of MI in ACS patients, but the risk of bleeding from intracranial hemorrhaging outweighs the benefit of MACE driven by MI. That is due to combination therapy having no positive impact on mortality; thus, the benefit-risk balance may be more favorable in patients with stable CAD.
BACKGROUND: Direct oral anticoagulants (DOACs) combined with antiplatelet therapy for acute coronary syndrome (ACS) may reduce ischemic events, but there is no consensus on bleeding risk. Moreover, the effect of DOACs on stable coronary artery disease (CAD) needs to be elucidated. We conducted a meta-analysis to summarize the efficacy and safety of DOACs combined with antiplatelet therapy in the treatment of stable CAD and ACS. METHODS: We searched PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials, then performed a systematic review of all 17 randomized controlled trials. RESULTS: For patients with stable CAD, DOACs combined with antiplatelet therapy significantly reduced the rate of major adverse cardiovascular events (MACE) (risk ratio; 95% confidence interval: 0.88; 0.81-0.95) and ischemic stroke (0.62; 0.50-0.77), with a relatively low risk of major bleeding (1.72; 1.42-2.07). For patients with ACS, the combination of DOACs reduced the risk of MACE (0.91; 0.85-0.97), myocardial infarction (MI) (0.90; 0.83-0.98), and ischemic stroke (0.75; 0.58-0.97), accompanied by increased non-fatal bleeding events and intracranial hemorrhage (3.42; 1.76-6.65). Results were similar when restricting the analysis to phase III studies except for the rate of stroke in patients with ACS. CONCLUSIONS: Combination therapy reduced the incidence of MI in ACS patients, but the risk of bleeding from intracranial hemorrhaging outweighs the benefit of MACE driven by MI. That is due to combination therapy having no positive impact on mortality; thus, the benefit-risk balance may be more favorable in patients with stable CAD.
Authors: Bassel Nazha; Bhavi Pandya; Jessica Cohen; Meng Zhang; Renato D Lopes; David A Garcia; Matthew W Sherwood; Alex C Spyropoulos Journal: Circulation Date: 2018-10-02 Impact factor: 29.690
Authors: Michelle L O'Donoghue; Christian T Ruff; Robert P Giugliano; Sabina A Murphy; Laura T Grip; Michele F Mercuri; Howard Rutman; Minggao Shi; Grzegorz Kania; Ondrej Cermak; Eugene Braunwald; Elliott M Antman Journal: Eur Heart J Date: 2015-02-16 Impact factor: 29.983
Authors: Jean-Philippe Collet; Marco Roffi; Robert A Byrne; Francesco Costa; Marco Valgimigli Journal: Eur Heart J Date: 2018-01-14 Impact factor: 29.983
Authors: Freek W A Verheugt; Jurriën M Ten Berg; Robert F Storey; Thomas Cuisset; Christopher B Granger Journal: J Am Coll Cardiol Date: 2019-07-02 Impact factor: 24.094
Authors: Vincent Andersson; Fredrik Bergström; Jonas Brånalt; Gunnar Grönberg; David Gustafsson; Staffan Karlsson; Magnus Polla; Joakim Bergman; Jan Kihlberg Journal: J Med Chem Date: 2016-07-12 Impact factor: 7.446
Authors: Jonathan L Halperin; Graeme J Hankey; Daniel M Wojdyla; Jonathan P Piccini; Yuliya Lokhnygina; Manesh R Patel; Günter Breithardt; Daniel E Singer; Richard C Becker; Werner Hacke; John F Paolini; Christopher C Nessel; Kenneth W Mahaffey; Robert M Califf; Keith A A Fox Journal: Circulation Date: 2014-06-03 Impact factor: 29.690
Authors: Arne Lauer; Waltraud Pfeilschifter; Chris B Schaffer; Eng H Lo; Christian Foerch Journal: Lancet Neurol Date: 2013-03-18 Impact factor: 44.182
Authors: Eleni Rapsomaniki; Marcus Thuresson; Erru Yang; Patrick Blin; Phillip Hunt; Sheng-Chia Chung; Dimitris Stogiannis; Mar Pujades-Rodriguez; Adam Timmis; Spiros C Denaxas; Nicolas Danchin; Michael Stokes; Florence Thomas-Delecourt; Cathy Emmas; Pål Hasvold; Em Jennings; Saga Johansson; David J Cohen; Tomas Jernberg; Nicholas Moore; Magnus Janzon; Harry Hemingway Journal: Eur Heart J Qual Care Clin Outcomes Date: 2016-07-01